Which has higher valuation & earnings, KTTA or TCRT?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A

Is KTTA or TCRT more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Alaunos Therapeutics N/A -165.94% -123.50%

Which has better valuation and earnings, KTTA or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is KTTA or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Alterity Therapeutics N/A N/A N/A

Which has stronger earnings and valuation, DWTX or KTTA?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is DWTX or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Pasithea Therapeutics N/A -57.44% -53.61%

Do analysts recommend KTTA or IZTC?

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 566.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Pasithea Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, KTTA or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is KTTA or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Invizyne Technologies N/A N/A N/A

Pasithea Therapeutics (KTTA) Competitors

$0.45 -0.01 (-1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$0.45 0.00 (0.00%)

As of 06:50 PM Eastern

Compare

KTTA vs. TCRT, MGX, ATHE, DWTX, and IZTC

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Alaunos Therapeutics (TCRT), Metagenomi (MGX), Alterity Therapeutics (ATHE), Dogwood Therapeutics (DWTX), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to Alaunos Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

In the previous week, Pasithea Therapeutics' average media sentiment score of 1.89 beat Alaunos Therapeutics' score of 1.87 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
Alaunos Therapeutics	Very Positive

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pasithea Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the broader market.

Pasithea Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 566.67%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Pasithea Therapeutics is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pasithea Therapeutics' return on equity of -57.44% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Summary

Pasithea Therapeutics beats Alaunos Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Metagenomi?

Pasithea Therapeutics (NASDAQ:KTTA) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Pasithea Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

23.9% of Pasithea Therapeutics shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pasithea Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 566.67%. Metagenomi has a consensus target price of $7.00, suggesting a potential upside of 464.52%. Given Pasithea Therapeutics' higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Pasithea Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Metagenomi	-384.61%	-51.23%	-36.62%

Pasithea Therapeutics has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Metagenomi	$25.21M	1.85	-$87.87M	-$2.30	N/A

In the previous week, Metagenomi had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for Metagenomi and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Metagenomi's score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
Metagenomi	Positive

Summary

Metagenomi beats Pasithea Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Pasithea Therapeutics' average media sentiment score of 1.89 beat Alterity Therapeutics' score of 1.25 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
Alterity Therapeutics	Positive

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Pasithea Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 566.67%. Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 161.04%. Given Pasithea Therapeutics' higher possible upside, equities analysts plainly believe Pasithea Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alterity Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats Pasithea Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 769.57%. Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 566.67%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 0.48 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Pasithea Therapeutics	Very Positive

Pasithea Therapeutics' return on equity of -57.44% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Dogwood Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Summary

Pasithea Therapeutics beats Dogwood Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Invizyne Technologies?

Pasithea Therapeutics (NASDAQ:KTTA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

23.9% of Pasithea Therapeutics shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Invizyne Technologies had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Invizyne Technologies' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
Invizyne Technologies	Neutral

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 566.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Pasithea Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Invizyne Technologies	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

Pasithea Therapeutics beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.40M	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-0.22	20.85	27.17	23.89
Price / Sales	N/A	304.49	526.21	92.07
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	0.19	8.26	10.69	6.18
Net Income	-$20.43M	$23.83M	$3.59B	$331.73M
7 Day Performance	-8.61%	-3.47%	-2.17%	-2.29%
1 Month Performance	-10.41%	3.44%	2.08%	-1.62%
1 Year Performance	-34.88%	44.52%	24.68%	16.81%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	3.5503 of 5 stars	$0.45 -1.6%	$3.00 +566.7%	-34.8%	$11.40M	N/A	N/A	3	Positive News
TCRT Alaunos Therapeutics	0.5963 of 5 stars	$2.07 +1.5%	N/A	-36.3%	$49.82M	N/A	N/A	40	Positive News High Trading Volume
MGX Metagenomi	2.9231 of 5 stars	$1.29 -2.3%	$7.00 +442.6%	-41.0%	$49.69M	$25.21M	N/A	236
ATHE Alterity Therapeutics	3.7234 of 5 stars	$5.58 +1.6%	$13.00 +133.0%	+9.7%	$48.68M	N/A	N/A	10	Gap Down
DWTX Dogwood Therapeutics	2.3688 of 5 stars	$1.41 -2.1%	$12.00 +751.1%	-69.6%	$48.43M	N/A	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. TCRT, MGX, ATHE, DWTX, and IZTC

How does Pasithea Therapeutics compare to Alaunos Therapeutics?

Summary

How does Pasithea Therapeutics compare to Metagenomi?

Summary

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Summary

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Summary

How does Pasithea Therapeutics compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. TCRT, MGX, ATHE, DWTX, and IZTC

How does Pasithea Therapeutics compare to Alaunos Therapeutics?

Does the media prefer KTTA or TCRT?

Do insiders & institutionals believe in KTTA or TCRT?

Which has more volatility and risk, KTTA or TCRT?

Do analysts recommend KTTA or TCRT?

Is KTTA or TCRT more profitable?

Which has higher valuation & earnings, KTTA or TCRT?

Summary

How does Pasithea Therapeutics compare to Metagenomi?

Which has more risk and volatility, KTTA or MGX?

Do insiders & institutionals hold more shares of KTTA or MGX?

Do analysts prefer KTTA or MGX?

Is KTTA or MGX more profitable?

Which has higher earnings and valuation, KTTA or MGX?

Does the media refer more to KTTA or MGX?

Summary

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Does the media refer more to KTTA or ATHE?

Do institutionals and insiders hold more shares of KTTA or ATHE?

Which has better valuation and earnings, KTTA or ATHE?

Which has more risk & volatility, KTTA or ATHE?

Do analysts recommend KTTA or ATHE?

Is KTTA or ATHE more profitable?

Summary

How does Pasithea Therapeutics compare to Dogwood Therapeutics?

Do institutionals and insiders have more ownership in DWTX or KTTA?

Do analysts rate DWTX or KTTA?

Does the media prefer DWTX or KTTA?

Is DWTX or KTTA more profitable?

Which has more risk and volatility, DWTX or KTTA?

Which has stronger earnings and valuation, DWTX or KTTA?

Summary

How does Pasithea Therapeutics compare to Invizyne Technologies?

Do insiders and institutionals have more ownership in KTTA or IZTC?

Does the media prefer KTTA or IZTC?

Do analysts recommend KTTA or IZTC?

Is KTTA or IZTC more profitable?

Which has preferable valuation & earnings, KTTA or IZTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools